Today: 20 March 2026
Subscribe
Browse Category

AMS:ASM 5 November 2025 - 25 January 2026

ASML stock price: what investors watch ahead of the Jan. 28 results

ASML stock price: what investors watch ahead of the Jan. 28 results

ASML closed at €1,178.20 in Amsterdam Friday, up 0.15%, ahead of its Q4 and full-year results set for Jan. 28. Morgan Stanley maintained ASML as a top pick and raised its price target to €1,400, citing expected order book improvement. Nasdaq shares last traded near $1,389, down 0.4%. ASML will announce an interim dividend Jan. 28, with ex-dividend date Feb. 9.
25 January 2026
···
Euronext Paris Shocks Markets with Historic Roots, Surging Stocks & Bold 2025 Moves

Euronext Stock Market Today, November 21, 2025: Tech Rout and Fed Jitters Drag European Indices Lower

The pan-European STOXX 600 fell about 1% Friday, hitting its lowest level since October as tech shares slumped and uncertainty over U.S. rate cuts weighed on markets. Amsterdam’s AEX, heavy in chip stocks, dropped 1.2%, leading declines among major EU benchmarks. By the close, Paris, Amsterdam, Frankfurt, and Milan indices all finished lower. U.S. jobs data and a global tech sell-off drove the losses.
21 November 2025
·······
AI Chip Boom, Google’s New Tricks, and Hollywood’s Robot Wars – Today’s AI News Roundup

$500 Billion Vanishes From Chip Stocks: Is the AI Boom Finally Hitting a Wall?

A global semiconductor selloff erased about $500 billion in market value as AI valuation fears spread from Wall Street to Asia and Europe. South Korea’s Kospi dropped as much as 6.2% intraday, while U.S. chip stocks and ETFs fell sharply after the Nasdaq slid 2% on Nov 4. Beijing ordered state-backed data centers to use only domestic AI chips, hitting Nvidia, AMD, and Intel. China will suspend some U.S. tariffs but keep a 13% levy on soybeans.
5 November 2025
········

Stock Market Today

  • Regeneus Ltd (RGS.AX) Jumps 33% on Heavy Volume, Signals Short-Term Upside
    March 19, 2026, 10:42 PM EDT. Regeneus Ltd (RGS.AX) surged 33.33% to A$0.012 on March 20, 2026, driven by unusually heavy volume of 4.28 million shares, nearly seven times the average. The stock broke above its 50-day and 200-day moving averages, indicating increased short-term trader interest in this clinical-stage biotech focused on osteoarthritis and wound healing. Despite negative earnings per share and liquidity constraints, the price action reflects momentum trading in a volatile sector. Traders should watch intraday support at A$0.010 and resistance near the year high of A$0.020. With a Meyka AI rating of 64.90 (Grade B), the stock is rated HOLD amid high volatility and thin order books typical of small-cap biotechs on the Australian Securities Exchange (ASX).
Go toTop